Dr. González-Martín on Updated PFS Data From the PRIMA Trial in Advanced Ovarian Cancer

Antonio Gonzalez-Martin, MD, PhD, discusses new long-term progression-free survival data from the phase 3 PRIMA trial in advanced ovarian cancer.

Antonio Gonzalez-Martin, MD, PhD, director, Department of Medical Oncology, Clinica Universidad de Navarra, discusses new long-term progression-free survival (PFS) data from the phase 3 PRIMA trial (NCT02655016) in advanced ovarian cancer.


The randomized phase 3 trial investigated the efficacy of niraparib (Zejula) as a maintenance treatment for patients with stage III or IV ovarian cancer who had previously completed frontline platinum-based chemotherapy.


Updated findings presented at the 2022 ESMO Congress demonstrated that the administration of niraparib improved median progression-free survival (PFS) benefit when compared with placebo, confirming its sustained benefit in reducing the risk of disease progression or death, Gonzalez-Martin states. Compared with the data presented at the 2019 ESMO Congress, which had a median follow-up of 1.2 years, the median follow-up for the updated results was 3.5 years with a data cut-off in November 2021.


These new results show that niraparib reduced the risk of progression or death by 55% in patients with homologous recombination deficiency (HRD) and increased median PFS in that population from 11.2 months to 24.5 months. Similarly, median PFS in the overall population was prolonged from 8.2 months to 13.8 months, reducing the risk of progression or death by 34%, Gonzalez-Martin concludes.

Related Videos
View All
Related Content